Categories Analysis, Finance

Morgan Stanley (MS) to report Q4 earnings on Thursday: What to expect

Morgan Stanley (NYSE: MS) is scheduled to report fourth quarter 2019 earnings results on Thursday, January 16, before the market opens. Analysts expect earnings of $1.02 per share which compares to EPS of $0.80 reported in the year-ago period. Revenue is expected to grow 14% to $9.7 billion.

In general, the banking industry is expected to be affected by lower interest rates and Morgan Stanley is no exception. The company is likely to see strength in investment banking and sales and trading continue in the fourth quarter.

Morgan Stanley (MS) exceeds Q3 expectations; stock gains

Last quarter, revenues in investment banking grew 5% and sales and trading rose 10%. While wealth management revenues saw little change, revenues in investment management jumped 17% helped by higher levels of assets under management and gains on carried interest.

The company’s stable business model is expected to drive growth in results. After seeing weakness in previous quarters, Morgan Stanley achieved revenue growth last quarter driven by strong performance across its business segments. The company’s efforts in reducing costs will also prove beneficial in the to-be-reported quarter.

Also read: Morgan Stanley Q3 2019 Earnings Conference Call Transcript

In the third quarter of 2019, Morgan Stanley beat revenue and earnings estimates. Revenue increased 2% to $10 billion while adjusted EPS increased 3% to $1.21.

Shares of Morgan Stanley have gained 25% over the past 12 months and 4% over the past one month. The stock has an average price target of $57.29.

This week will see several banks report their earnings including JPMorgan (NYSE: JPM), Citigroup (NYSE: C), Wells Fargo (NYSE: WFC) and Goldman Sachs (NYSE: GS).

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top